Who Sold, Who Bought, Who Waits: A Post-Placing Checklist for UK Small-Cap Analysts

Secondary raises have become a routine feature of the UK small- and mid-cap landscape. A company that has spent eighteen months trimming costs and talking up its order book can, within a single morning, issue paper at a double-digit discount through an accelerated bookbuild and move on to the next press release. For the analyst on the receiving end of that announcement, the temptation is to treat the raise as a financing footnote and get back to the operating model. That instinct is usually wrong.

The share price reaction in the first two sessions is dominated by mechanics: index weightings, forced selling by holders who cannot participate, and the arithmetic of dilution. The analytical work that matters happens afterwards, in the four to twelve weeks before the next results, when the new shares settle into the register and the market begins to test whether the money was needed and whether it will be well spent.

Begin With the Authority, Not the Discount

Before assessing the price, establish how the company was permitted to issue. Most UK placings rely on the disapplication of pre-emption rights approved at the last general meeting, typically within the Pre-emption Group's stated parameters: a routine authority of up to 10% of issued share capital, plus an additional amount connected to a specified acquisition. Where the company has gone beyond those limits, or has returned to the market more than once inside a twelve-month window, the governance signal deserves attention in its own right.

Record the discount against the closing mid-price, but record also the discount against the volume-weighted price of the preceding five days and against any recent broker target. A 12% discount to the screen price can look modest if the stock had already drifted 20% from its spring highs; it can look aggressive if the register is tightly held and the free float is thin. The relevant comparison is the discount required to clear the book, not the discount that appears in the headline.

Use of Proceeds: Verbs Matter More Than Nouns

Companies describe proceeds in nouns \u2014 working capital, balance sheet flexibility, growth investment. Analysts should look for verbs. What, specifically, will be funded, by when, and at what cost? A raise framed around a named contract with a stated start date and a disclosed capital requirement is auditable. A raise framed around "accelerating the growth trajectory" is not.

Three tests are worth applying consistently. First, does the amount raised map credibly onto a disclosed funding need, or is it a round number that happens to cover twelve months of cash burn? Second, does the stated use of proceeds appear in the subsequent interim statement, or does it quietly migrate? Third, if the raise is partly defensive \u2014 covenant headroom, supplier terms, customer confidence \u2014 does management say so plainly? Candour about defensive raises tends to be rewarded; euphemism tends to be remembered at the next raise, when the discount is wider.

Participation Is a Data Point, Not a Vote of Confidence

Institutional participation is frequently cited as validation. Treat it as information rather than endorsement. Existing holders who take up a placing are often protecting a position size rather than expressing a fresh view, and new holders entering at a discount have a built-in cushion that the market does not share.

The more revealing disclosures concern the board. Director participation, whether in the placing itself or in a subsequent open offer, is a genuine signal, particularly where directors have recently received shares through remuneration rather than purchase. Where the company operates an open offer alongside the placing, examine the take-up. A low take-up is not automatically negative \u2014 retail holders face frictions and deadlines \u2014 but a take-up that falls well short of expectations, combined with limited director participation, tells you something about how the register itself views the terms.

The Supply Calendar Matters More Than the Day-One Print

Newly issued shares do not arrive with the same horizon. Placing shares are typically admitted within days and are freely tradable; director and management lock-ups usually run from 90 to 180 days, occasionally twelve months for controlling shareholders; warrants and broker options may sit further out. Build a simple calendar: dates on which lock-ups lapse, dates on which open offer shares are admitted, dates on which any convertible or warrant overhang becomes exercisable.

Overlay that calendar on expected news flow. If a lock-up expires two weeks before a trading update, the market is being asked to absorb supply into an information vacuum, and the stock may trade soft regardless of fundamentals. If, conversely, a lock-up lapses just after a well-received set of results, the risk is lower. The same principle applies to clawback and commission arrangements: where a broker's fee is partly payable in shares subject to clawback, the intermediary has an incentive to support the aftermarket, and that support tends to fade once the clawback period ends.

Reading the Broker's Behaviour

Who ran the book, and how was it run? An accelerated bookbuild launched after the close and completed before the open is efficient, but it also compresses price discovery. Where a company switches from a long-standing adviser to a new broker for the raise, ask why. Where a broker's research coverage has been intermittent, a raise that suddenly generates a note with an unchanged target price is worth reading closely for the assumptions behind it.

Translating the Audit into Numbers

Once the qualitative work is done, the modelling should be mechanical. Rebuild the share count on a fully diluted basis, including any options or warrants whose exercise price now sits in the money. Recalculate earnings per share and any per-share dividend metric on the enlarged base. Adjust net debt for the net proceeds and check whether the raise triggers any covenant recalculation or fee amortisation. Then, and only then, revisit the valuation: a lower enterprise value is not the same as a cheaper equity, and a discounted raise can leave a stock optically cheaper while leaving shareholders worse off on a per-share basis.

Finally, form a pre-results stance and write it down: what the raise must deliver for the dilution to have been justified, which disclosure would confirm it, and which would falsify it. That record is what separates an analyst who reacted to an announcement from one who has actually audited it. In a market where secondary raises arrive with little warning, the discipline of the follow-up is the durable edge.